Quidel Corp
NASDAQ:QDEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shriram Finance Ltd
NSE:SHRIRAMFIN
|
IN |
Quidel Corp
Long-Term Debt
Quidel Corp
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Quidel Corp
NASDAQ:QDEL
|
Long-Term Debt
$2.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
33%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Long-Term Debt
$920m
|
CAGR 3-Years
7%
|
CAGR 5-Years
26%
|
CAGR 10-Years
9%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Long-Term Debt
$1.3B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
251%
|
CAGR 10-Years
N/A
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Long-Term Debt
$568.7m
|
CAGR 3-Years
1%
|
CAGR 5-Years
24%
|
CAGR 10-Years
5%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Long-Term Debt
$734m
|
CAGR 3-Years
58%
|
CAGR 5-Years
16%
|
CAGR 10-Years
14%
|
|
Quidel Corp
Glance View
Quidel Corporation, a player in the diagnostic healthcare industry, has steadily navigated the labyrinth of medical innovation, carving out a niche in rapid diagnostic testing. Born out of a mission to streamline the process of disease detection, Quidel has leveraged biotechnology to develop fast, reliable diagnostic solutions that address widespread health issues. This company’s arsenal includes tests for infectious diseases, reproductive health, and autoimmune disorders—each meticulously designed to expedite the diagnostic process while maintaining a stringent commitment to accuracy. By fostering partnerships with healthcare providers and aligning with technological advancements, Quidel has positioned itself as indispensable in the clinic setting, where swift decision-making can significantly impact patient care. At the heart of Quidel's business model is its focus on providing tangible value to both healthcare professionals and patients. The company generates revenue primarily through the sale of its diagnostic products, which are utilized in settings ranging from small clinics to large hospital networks. Quidel's innovative platforms, like the Sofia and Solana systems, are lauded for their efficiency and ease of use, attributes that resonate particularly well in medical environments under pressure to deliver fast and effective results. By effectively converting scientific expertise into practical and user-friendly applications, Quidel not only enhances patient outcomes but also fortifies its financial standing within the competitive landscape of medical diagnostics.
See Also
What is Quidel Corp's Long-Term Debt?
Long-Term Debt
2.5B
USD
Based on the financial report for Dec 28, 2025, Quidel Corp's Long-Term Debt amounts to 2.5B USD.
What is Quidel Corp's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
33%
Over the last year, the Long-Term Debt growth was 15%. The average annual Long-Term Debt growth rates for Quidel Corp have been 1% over the past three years , and 33% over the past ten years .